Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12107712 | 0.90 | SLC1A2 (0.40) | SMN1; SMN2LMNATSHRHTTGAA | |
| SCHEMBL16652232 | 0.83 | TSHR (0.44) | SMN1; SMN2TSHRHTTGAASLC1A2 | |
| SCHEMBL10037495 | 0.83 | SLC1A2 (0.42) | SMN1; SMN2LMNATSHRHTTGAA | |
| SCHEMBL30269173 | 0.82 | TERT (0.40) | SMN1; SMN2TSHRHTTGAASLC1A2 | |
| SCHEMBL17841877 | 0.82 | TERT (0.40) | SMN1; SMN2TSHRHTTGAASLC1A2 | |
| SCHEMBL9457039 | 0.77 | SLC1A2 (0.40) | SMN1; SMN2LMNATSHRHTTGAA | |
| SCHEMBL10037552 | 0.76 | SLC1A2 (0.35) | SMN1; SMN2LMNATSHRHTTGAA | |
| SCHEMBL3517842 | 0.75 | MME (0.52) | POLB | |
| SCHEMBL21408701 | 0.75 | MEN1 (0.47) | SMN1; SMN2SLC1A2MEN1KMT2A | |
| SCHEMBL12505905 | 0.74 | HTT (0.35) | HTTPOLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170143843-A1 | ANTI-FACTOR D ANTIBODY VARIANT CONJUGATES AND USES THEREOF | GENENTECH INC (US) | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170143843-A1 | ANTI-FACTOR D ANTIBODY VARIANT CONJUGATES AND USES THEREOF | CFD, CFH, F13B | SMN1; SMN2 2938/4885LMNA 1131/4885PAX8 3457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.